
					Posted by Chloe McGuire on Apr 14th, 2019 // Comments off Intercept Pharmaceuticals (NASDAQ:ICPT) has been assigned a $251.00 price objective by equities researchers at Wedbush  in a research note issued on Friday, TipRanks reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 163.63% from the company’s current price.A number of other research firms have also recently weighed in on ICPT. Credit Suisse Group  reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, February 12th. Raymond James  reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, February 14th. Needham & Company LLC raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Thursday, January 24th. BidaskClub downgraded Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 23rd. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a research note on Monday, December 31st. Two analysts have rated the stock with a sell rating, five have assigned  a hold rating and seventeen have assigned  a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $144.05.ICPT stock opened at $95.21 on Friday. Intercept Pharmaceuticals has a twelve month low of $64.50 and a twelve month high of $133.74. The company has a debt-to-equity ratio of 19.41, a quick ratio of 4.22 and a current ratio of 4.22. The stock has a market cap of $2.83 billion, a PE ratio of -8.77 and a beta of 1.63.  In other Intercept Pharmaceuticals news, insider David Shapiro sold 562 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $115.01, for a total value of $64,635.62. Following the sale, the insider now owns 40,061 shares of the company’s stock, valued at approximately $4,607,415.61. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Srinivas Akkaraju sold 23,438 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $128.78, for a total value of $3,018,345.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,504 shares of company stock worth $3,779,947. Corporate insiders own  4.90% of the company’s stock. Large investors have recently added to or reduced their stakes in the business. Strs Ohio increased its stake in  Intercept Pharmaceuticals by 30.0% in the 4th quarter. Strs Ohio now owns 1,300 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 300 shares during the last quarter.  Sofinnova Investments Inc. bought a new stake in  Intercept Pharmaceuticals in the 4th quarter worth approximately $5,491,000.  Vanguard Group Inc increased its stake in  Intercept Pharmaceuticals by 2.8% in the 3rd quarter. Vanguard Group Inc now owns 1,952,931 shares of the biopharmaceutical company’s stock worth $246,772,000 after acquiring an additional 54,038 shares during the last quarter.  Macquarie Group Ltd. increased its stake in  Intercept Pharmaceuticals by 158.8% in the 3rd quarter. Macquarie Group Ltd. now owns 35,561 shares of the biopharmaceutical company’s stock worth $4,493,000 after acquiring an additional 21,819 shares during the last quarter.  Finally, AQR Capital Management LLC bought a new stake in  Intercept Pharmaceuticals in the 3rd quarter worth approximately $2,764,000. 70.24% of the stock is currently owned by institutional investors and hedge funds. About Intercept PharmaceuticalsIntercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).Featured Article: What are Closed-End Mutual Funds?Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.Hollysys Automation Technologies (HOLI) Rating Lowered to Strong Sell at ValuEngine‘Fascination with authoritarianism’ worries president